Viridian Therapeutics, Inc./DE (VRDN) Return on equity 2017–2025
Viridian Therapeutics, Inc./DE (VRDN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.4%FY2025 · since FY2017: -68.8% → -47.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.4% | -7.2 pp |
| FY2024 | -40.2% | +13.6 pp |
| FY2023 | -53.8% | -20.9 pp |
| FY2022 | -32.9% | +9.4 pp |
| FY2021 | -42.3% | +49.9 pp |
| FY2020 | -92.2% | +173.6 pp |
| FY2019 | -265.8% | -202.1 pp |
| FY2018 | -63.7% | +5.2 pp |
| FY2017 | -68.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice